Sentences with phrase «global change program»

Despite the requirements of the 1990 law, the White House has substantial power to derail such assessments, said Nicky Sundt, who managed communications for the global change program office through most of the two terms of George W. Bush.

But on the EPA global change program website we look in vain for publications, or even current project descriptions, since 2002 that would document the progress and results of this research agenda.

On March 20, 2015, Director Susan Hassol and Science Advisor Michael E. Mann led a climate communication workshop for the fellows of Virginia Tech's Interfaces of Global Change program.

Jessica Tierney, lead scientist on the project and currently a post-doctoral researcher with National Oceanographic and Atmospheric Administration's Climate and Global Change program, analyzed core samples from the lake floor to deduce lake surface temperatures over the past 1,500 years.

On March 20, 2015, Director Susan Hassol and Science Advisor Michael E. Mann led a climate communication workshop for the fellows of Virginia Tech's Interfaces of Global Change program.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

«Our applicants realize the global energy industry is undergoing profound change and that they need more skills and knowledge to prosper,» says Claire Dixon, Haskayne's director of MBA programs.

To address this changing market, Laureate will provide $ 13 million to help Thunderbird create new online and undergraduate programs, while also expanding its global footprint.

Enter the DO School, a global institution that, for select programs, borrows students passionate about social change from accredited colleges and offers them experiential learning through doing, challenging them to solve real - world, pressing problems in sustainable ways.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

United States Global Change Research Program / Cooperative Institute for Climate and Satellites

Our analysis shows the overall economy improves, taxes are lower and pollution emissions are reduced,» said John M. Reilly, co-director of MIT's Joint Program on the Science and Policy of Global Change.

Franklin Templeton's global volunteer program, Involved, empowers employees to use their time, talent and skills to make positive changes in our communities.

The US Global Change Research Program is required by statute to produce the comprehensive National Climate Assessment report on climate change impacts on the United States every four Change Research Program is required by statute to produce the comprehensive National Climate Assessment report on climate change impacts on the United States every four change impacts on the United States every four years.

The ministry delivers a range of programs, services and tools to help businesses innovate and compete in today's fast - changing global economy, including business support and youth entrepreneurship programs, strategic investments and international trade and export expertise.

This new program recognizes and supports young Canadians who work in the international arena on the most pressing challenges of this century including political unrest, climate change, human rights and global health pandemics.

Examples of these risks, uncertainties and other factors include, but are not limited to the impact of: adverse general economic and related factors, such as fluctuating or increasing levels of unemployment, underemployment and the volatility of fuel prices, declines in the securities and real estate markets, and perceptions of these conditions that decrease the level of disposable income of consumers or consumer confidence; adverse events impacting the security of travel, such as terrorist acts, armed conflict and threats thereof, acts of piracy, and other international events; the risks and increased costs associated with operating internationally; our expansion into and investments in new markets; breaches in data security or other disturbances to our information technology and other networks; the spread of epidemics and viral outbreaks; adverse incidents involving cruise ships; changes in fuel prices and / or other cruise operating costs; any impairment of our tradenames or goodwill; our hedging strategies; our inability to obtain adequate insurance coverage; our substantial indebtedness, including the ability to raise additional capital to fund our operations, and to generate the necessary amount of cash to service our existing debt; restrictions in the agreements governing our indebtedness that limit our flexibility in operating our business; the significant portion of our assets pledged as collateral under our existing debt agreements and the ability of our creditors to accelerate the repayment of our indebtedness; volatility and disruptions in the global credit and financial markets, which may adversely affect our ability to borrow and could increase our counterparty credit risks, including those under our credit facilities, derivatives, contingent obligations, insurance contracts and new ship progress payment guarantees; fluctuations in foreign currency exchange rates; overcapacity in key markets or globally; our inability to recruit or retain qualified personnel or the loss of key personnel; future changes relating to how external distribution channels sell and market our cruises; our reliance on third parties to provide hotel management services to certain ships and certain other services; delays in our shipbuilding program and ship repairs, maintenance and refurbishments; future increases in the price of, or major changes or reduction in, commercial airline services; seasonal variations in passenger fare rates and occupancy levels at different times of the year; our ability to keep pace with developments in technology; amendments to our collective bargaining agreements for crew members and other employee relation issues; the continued availability of attractive port destinations; pending or threatened litigation, investigations and enforcement actions; changes involving the tax and environmental regulatory regimes in which we operate; and other factors set forth under «Risk Factors» in our most recently filed Annual Report on Form 10 - K and subsequent filings by the Company with the Securities and Exchange Commission.

Global Skills Strategy and express entry changes and the startup visa program, all those things show that this is something we've been working on.

«Global Strategy,» a new program of evangelism, was introduced at the recent session, and its emphasis could change Adventism considerably.

Responding to a recent article in Nature on the psychology of climate change, The Guardian «s Andrew Brown argues that combatting global warming will require something beyond carbon taxes, recycling programs, and technological innovation: There may be ways of fixing [the current....

This year's program is set to probe critical global issues from Brexit to climate change, explore the growing sustainability movement, delve into new technology available to the wine trade, and shine the spotlight on small and organic growers.

This year's program is set to probe critical global issues from Brexit to climate change, explore the growing sustainability movement, delve -LSB-...]

Nine Mid-Atlantic and New England states have agreed to cut power plant greenhouse gas emissions across the region by 65 percent by 2030 through the nation's first cap - and - trade program to reduce carbon contributing to global climate change.

In the waning months of the Bloomberg administration, however, the iZone initiative, and schools like Global Tech — which have benefited from extra funding and support offered through the program — are being buffeted by a series of changes, from budget cuts to city - wide implementation of the Common Core state standards.

Since 1977, IIASA's annual 3 - month Young Scientists Summer Program (YSSP) offers research opportunities to talented young researchers whose interests correspond with IIASA's ongoing research on issues of global environmental, economic and social change.

The U.S. Global Change Research Program (USGCRP), which produced the report, coordinates climate research across 13 departments and agencies.

The draft report by the U.S. Global Change Research Program says it is likely the world will forfeit its ability to meet «rapid emission reduction» scenarios needed to stabilize greenhouse gas concentrations «within a few years.»

The Global Change Education Program provides opportunities to participate in research areas related to global cGlobal Change Education Program provides opportunities to participate in research areas related to global cChange Education Program provides opportunities to participate in research areas related to global cglobal changechange.

Over the next century, the global thermostat will probably ratchet up another 2 to 12 degrees on average, according to a 2009 report from the U.S. Global Change Research Prglobal thermostat will probably ratchet up another 2 to 12 degrees on average, according to a 2009 report from the U.S. Global Change Research PrGlobal Change Research Program.

She is also a faculty affiliate of the MIT Joint Program on the Science and Policy of Global Change and the MIT Energy Initiative.

- National Oceanic and Atmospheric Administration (NOAA) Climate and Global Change Postdoctoral Fellowship Program

The assessment is produced through the U.S. Global Change Research Program, a collaboration of 13 federal agencies and departments with authors from the government and a wide swath of academia.

That statement — which indicates a 95 to 100 percent confidence in the finding — came in a report released November 3 by the U.S. Global Change Research Program.

The United Nations Environment Program warns that global emissions of greenhouse gases are opening up a widening gap between reality and climate change goals

Emily's background is in ecology and environmental policy, and prior to joining AAAS, she led engagement and outreach efforts at the U.S. Global Change Research Program.

Cooney himself made 294 edits to the administration's 364 - page Strategic Plan for the U.S. Climate Change Science Program posted July 24, 2003, «to exaggerate or emphasize scientific uncertainties or to deemphasize or diminish the importance of the human role in global warming,» and Cooney and the CEQ played a role in eliminating climate change sections in the EPA's draft Report on the Environment as well as its National Air Quality and Emissions Trends RChange Science Program posted July 24, 2003, «to exaggerate or emphasize scientific uncertainties or to deemphasize or diminish the importance of the human role in global warming,» and Cooney and the CEQ played a role in eliminating climate change sections in the EPA's draft Report on the Environment as well as its National Air Quality and Emissions Trends Rchange sections in the EPA's draft Report on the Environment as well as its National Air Quality and Emissions Trends Report.

«In studying one of the most dramatic episodes of global change since the end of the age of the dinosaurs, these scientists show that we are currently in uncharted territory in the rate carbon is being released into the atmosphere and oceans,» says Candace Major, program director in the National Science Foundation (NSF)'s Division of Ocean Sciences, which funded the research.

Of the $ 1.65 million for biodiversity and climate change work, $ 750,000 is for a global change research program primarily dealing with long - term forest research, $ 250,000 for a species identification program called Barcode of Life, and $ 300,000 for an online database of species called the Encyclopedia of Life.

NASA's Global Climate Change Program has reported that «the 10 warmest years in the 134 - year record all have occurred since 2000, with the exception of 1998,» and the year 2015 ranks as the warmest on record.

In New York City, the average temperature has increased about four degrees Fahrenheit since 1880, and could get 10 degrees hotter by 2100, according to a study commissioned by the federally funded U.S. Global Change Research Program.

That desire of balance lead the program's creators to avoid terms like «climate change» or «global warming» in lesson plans, Rowe said, «which would have sent a biased point of view.»

Climate Science Special Report: Fourth National Climate Assessment, Volume I. U.S. Global Change Research Program.

The occasion was the release of a report from the U.S. Global Change Research Program titled Global Climate Change Impacts in the United States.

Until 2001, she worked at the NationalAcademies» National Research Council over a 17 - year period, serving in several capacities — Executive Director of the Board on Sustainable Development, where she directed the Sustainability Transition Study and the Global Change Research Program; director of international organization programs for the Office of International Affairs; and Director of the Polar Research Board.

«In the Southwest, water availability for irrigation is already a concern,» says first author Elodie Blanc, a research scientist at MIT's Joint Program on the Science and Policy of Global Change.

The full report is due to be published in the spring by the US Global Change Research Program, a body charged by Congress with assessing climatic impacts on the US every four years.

Henry Jacoby, an economist and former director of the Joint Program on the Science and Policy of Global Change at Massachusetts Institute of Technology in Cambridge, agrees.

Earth science would grow from $ 1.439 billion to $ 1.797 billion in 2012, though House of Representatives Republicans are sure to attack a program focused on understanding global change.

«As significant alterations to ecosystems resulting from global change become more likely, environmental scientists and the general public need to appreciate some of the potential outcomes,» says senior author Andrew Friedland (http://envs.dartmouth.edu/people/andrew-j-friedland), a professor in Dartmouth's Environmental Studies Program.

The National Oceanic and Atmospheric Administration is the lead federal agency on the report for the U.S. Global Change Research Program, which produced Volume 1 of the 4th National Climate Assessment.